Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.56
UTHR's Cash to Debt is ranked higher than
63% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. UTHR: 1.56 )
UTHR' s 10-Year Cash to Debt Range
Min: 0.69   Max: 15951.56
Current: 1.56

0.69
15951.56
Equity to Asset 0.60
UTHR's Equity to Asset is ranked higher than
69% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. UTHR: 0.60 )
UTHR' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.97
Current: 0.6

0.37
0.97
Interest Coverage 16.20
UTHR's Interest Coverage is ranked higher than
55% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. UTHR: 16.20 )
UTHR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 3302.25
Current: 16.2

2.02
3302.25
F-Score: 6
Z-Score: 6.97
M-Score: -2.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.94
UTHR's Operating margin (%) is ranked higher than
97% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. UTHR: 38.94 )
UTHR' s 10-Year Operating margin (%) Range
Min: -24714.81   Max: 46.03
Current: 38.94

-24714.81
46.03
Net-margin (%) 23.41
UTHR's Net-margin (%) is ranked higher than
94% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. UTHR: 23.41 )
UTHR' s 10-Year Net-margin (%) Range
Min: -23703.7   Max: 56.09
Current: 23.41

-23703.7
56.09
ROE (%) 24.00
UTHR's ROE (%) is ranked higher than
96% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. UTHR: 24.00 )
UTHR' s 10-Year ROE (%) Range
Min: -76.65   Max: 36.15
Current: 24

-76.65
36.15
ROA (%) 14.43
UTHR's ROA (%) is ranked higher than
96% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. UTHR: 14.43 )
UTHR' s 10-Year ROA (%) Range
Min: -68.45   Max: 22.31
Current: 14.43

-68.45
22.31
ROC (Joel Greenblatt) (%) 94.51
UTHR's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. UTHR: 94.51 )
UTHR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1372.3   Max: 90.19
Current: 94.51

-1372.3
90.19
Revenue Growth (%) 28.20
UTHR's Revenue Growth (%) is ranked higher than
92% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. UTHR: 28.20 )
UTHR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 231.7
Current: 28.2

0
231.7
EBITDA Growth (%) 24.00
UTHR's EBITDA Growth (%) is ranked higher than
93% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. UTHR: 24.00 )
UTHR' s 10-Year EBITDA Growth (%) Range
Min: -56   Max: 127.7
Current: 24

-56
127.7
EPS Growth (%) 20.60
UTHR's EPS Growth (%) is ranked higher than
91% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. UTHR: 20.60 )
UTHR' s 10-Year EPS Growth (%) Range
Min: -50.4   Max: 153.6
Current: 20.6

-50.4
153.6
» UTHR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

UTHR Guru Trades in Q3 2013

Joel Greenblatt 372,147 sh (+9.03%)
Vanguard Health Care Fund Sold Out
David Dreman Sold Out
John Hussman 358,000 sh (-23.5%)
Jim Simons 440,778 sh (-25.34%)
Paul Tudor Jones 7,700 sh (-50.64%)
» More
Q4 2013

UTHR Guru Trades in Q4 2013

Steven Cohen 24,174 sh (New)
Paul Tudor Jones 5,100 sh (-33.77%)
Joel Greenblatt 194,595 sh (-47.71%)
Jim Simons 224,278 sh (-49.12%)
John Hussman 134,000 sh (-62.57%)
» More
Q1 2014

UTHR Guru Trades in Q1 2014

Paul Tudor Jones 9,167 sh (+79.75%)
Joel Greenblatt 316,489 sh (+62.64%)
Jim Simons 287,940 sh (+28.39%)
John Hussman 134,000 sh (unchged)
Steven Cohen 2,497 sh (-89.67%)
» More
Q2 2014

UTHR Guru Trades in Q2 2014

Joel Greenblatt 646,066 sh (+104.14%)
John Hussman 134,000 sh (unchged)
Paul Tudor Jones 8,168 sh (-10.9%)
Jim Simons 252,478 sh (-12.32%)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Add 104.14%0.37%$86.14 - $107.81 $ 128.2833%646066
Joel Greenblatt 2014-03-31 Add 62.64%0.17%$90.67 - $113.39 $ 128.2825%316489
John Hussman 2013-12-31 Reduce -62.57%1%$80.03 - $114.51 $ 128.2843%134000
Joel Greenblatt 2013-12-31 Reduce -47.71%0.45%$80.03 - $114.51 $ 128.2843%194595
John Hussman 2013-09-30 Reduce -23.5%0.33%$66.1 - $79.58 $ 128.2876%358000
Vanguard Health Care Fund 2013-09-30 Sold Out 0.32%$66.1 - $79.58 $ 128.2876%0
David Dreman 2013-09-30 Sold Out 0.12%$66.1 - $79.58 $ 128.2876%0
Joel Greenblatt 2013-06-30 Add 15.34%0.13%$59.64 - $69.31 $ 128.2899%341330
David Dreman 2012-12-31 New Buy0.09%$44.99 - $58.91 $ 128.28146%57025
John Hussman 2012-09-30 New Buy0.67%$49.73 - $58.2 $ 128.28137%500000
Joel Greenblatt 2012-06-30 Add 101.59%0.6%$41.19 - $49.51 $ 128.28191%332744
Richard Perry 2012-06-30 Sold Out 0.04%$41.19 - $49.51 $ 128.28191%0
Joel Greenblatt 2012-03-31 Add 82.68%0.31%$45.54 - $50.99 $ 128.28184%165063
Richard Perry 2012-03-31 New Buy0.04%$45.54 - $50.99 $ 128.28184%15300
Joel Greenblatt 2011-12-31 Add 38.75%0.15%$37.21 - $47.54 $ 128.28209%90355
Joel Greenblatt 2011-09-30 Add 274.82%0.29%$37.47 - $57.38 $ 128.28165%65122
Vanguard Health Care Fund 2011-09-30 Add 77.9%0.16%$37.47 - $57.38 $ 128.28165%1787000
Michael Price 2011-09-30 Sold Out 0.1%$37.47 - $57.38 $ 128.28165%0
George Soros 2011-09-30 Sold Out 0.0776%$37.47 - $57.38 $ 128.28165%0
Michael Price 2011-06-30 Reduce -82.59%0.59%$53.49 - $70.7 $ 128.28102%12500
Vanguard Health Care Fund 2011-06-30 Add 183.36%0.18%$53.49 - $70.7 $ 128.28102%1004500
Joel Greenblatt 2011-06-30 New Buy0.13%$53.49 - $70.7 $ 128.28102%17374
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about United Therapeutics Corp

High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares
Yesterday insider executives made large sells at Facebook Inc. (FB), United Therapeutics Corporation (UTHR) and Hillenbrand Inc. (HI), all companies held by billionaires. Here are the company updates and trade highlights. Read more...
Vanguard Health Care Fund Selling Update
The updated portfolio of the Vanguard Health Care Fund lists 92 stocks, four of them new, a total value at $29.45 billion, and a quarter-over-quarter turnover of 4%. The portfolio is weighted with two sectors: health care at 91.5% and consumer defensive at 2.9%. Vanguard Health Care Fund has averaged a return of 24.96% over 12 months and 9.5% over 10 years, according to the GuruFocus Score Board of Gurus. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.20
UTHR's P/E(ttm) is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 25.20 )
UTHR' s 10-Year P/E(ttm) Range
Min: 8.83   Max: 218.78
Current: 25.2

8.83
218.78
P/B 5.16
UTHR's P/B is ranked higher than
77% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. UTHR: 5.16 )
UTHR' s 10-Year P/B Range
Min: 2.01   Max: 10.39
Current: 5.16

2.01
10.39
P/S 5.85
UTHR's P/S is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. UTHR: 5.85 )
UTHR' s 10-Year P/S Range
Min: 2.83   Max: 18.02
Current: 5.85

2.83
18.02
PFCF 28.96
UTHR's PFCF is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 28.96 )
UTHR' s 10-Year PFCF Range
Min: 9.7   Max: 666.33
Current: 28.96

9.7
666.33
EV-to-EBIT 12.51
UTHR's EV-to-EBIT is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 12.51 )
UTHR' s 10-Year EV-to-EBIT Range
Min: 5.5   Max: 363.2
Current: 12.51

5.5
363.2
PEG 0.37
UTHR's PEG is ranked higher than
100% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 0.37 )
UTHR' s 10-Year PEG Range
Min: 0   Max: 5.09
Current: 0.37

0
5.09
Shiller P/E 42.27
UTHR's Shiller P/E is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 42.27 )
UTHR' s 10-Year Shiller P/E Range
Min: 25   Max: 129.35
Current: 42.27

25
129.35
Current Ratio 1.34
UTHR's Current Ratio is ranked higher than
54% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. UTHR: 1.34 )
UTHR' s 10-Year Current Ratio Range
Min: 0.96   Max: 64.22
Current: 1.34

0.96
64.22
Quick Ratio 1.25
UTHR's Quick Ratio is ranked higher than
57% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. UTHR: 1.25 )
UTHR' s 10-Year Quick Ratio Range
Min: 0.9   Max: 64.22
Current: 1.25

0.9
64.22

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.23
UTHR's Price/Tangible Book is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. UTHR: 5.23 )
UTHR' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 17.88
Current: 5.23

1.16
17.88
Price/DCF (Projected) 2.25
UTHR's Price/DCF (Projected) is ranked higher than
96% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 2.25 )
UTHR' s 10-Year Price/DCF (Projected) Range
Min: 1.37   Max: 232.67
Current: 2.25

1.37
232.67
Price/Median PS Value 0.77
UTHR's Price/Median PS Value is ranked higher than
92% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. UTHR: 0.77 )
UTHR' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 287.5
Current: 0.77

0.42
287.5
Price/Graham Number 2.24
UTHR's Price/Graham Number is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. UTHR: 2.24 )
UTHR' s 10-Year Price/Graham Number Range
Min: 0.99   Max: 5.79
Current: 2.24

0.99
5.79
Earnings Yield (Greenblatt) 8.00
UTHR's Earnings Yield (Greenblatt) is ranked higher than
83% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. UTHR: 8.00 )
UTHR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 18
Current: 8

0.3
18
Forward Rate of Return (Yacktman) 1.32
UTHR's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. UTHR: 1.32 )
UTHR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.7   Max: 2.3
Current: 1.32

-4.7
2.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UTH.Germany
United Therapeutics Corporation was incorporated in Delaware in June 1996. The Company is a biotechnology company, which is focused on the development and commercialization of products to address the medical needs of patients with chronic and life-threatening conditions. The Company operates two business segments: pharmaceuticals and telemedicine. The pharmaceutical segment includes all activities associated with the research, development, manufacturing and commercialization of its therapeutic products. The telemedicine segment includes all activities associated with the development and manufacturing of patient cardiac monitoring products and services. Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Monoclonal Antibodies (MAbs),Glycobiology Antiviral Agents, and Cell-Based Therapy. Prostacyclin analogues are stable synthetic forms of prostacyclin, an important molecule produced by the body that has powerful effects on blood vessel health and function. Its product Remodulin (treprostinil) Injection (Remodulin) to be administered subcutaneously or intravenously for the treatment of pulmonary arterial hypertension (PAH). PDE-5 inhibitors act to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in cells. cGMP is activated by nitric oxide (NO) to effect relaxation of vascular smooth muscle. Its PDE-5 inhibitor product is Adcirca (tadalafil) tablets (Adcirca), a once-daily oral therapy for the treatment of PAH. MAbs act by targeting tumor-associated antigens on cancer cells to activate a patient's immune system against the cancer cells. The Company is developing the antibody Ch14.18 MAb for the treatment of neuroblastoma, under an agreement with the National Cancer Institute. Glycobiology antiviral agents are a novel class of small, sugar-like molecules that have shown pre-clinical indications of efficacy against a broad range of viruses. The Company generates revenues mainly from the sale of Remodulin, Tyvaso and Adcirca. The Company competes with the developers, manufacturers and distributors of all of these products for customers, funding, access to licenses, personnel, third-party collaborators, product development and commercialization.
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
Here are 5 Good Companies to Consider Investing In Right Now Feb 11 2014 
High-Dollar Insider Sells - Zuckerberg Sells 41M Facebook Shares Dec 27 2013 
John Hussman's Third Quarter Top 5 Nov 07 2013 
Vanguard Health Care Fund Selling Update Oct 30 2013 
comment on UTHR May 11 2013 
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Fast-Growing Small-Cap Stocks to Watch Mar 26 2013 
comment on UTHR Mar 23 2013 
fd Jan 12 2013 
bmn Jan 12 2013 

More From Our Partners
Axsome Therapeutics Announces Appointments to Its Board of Directors Sep 17 2014 - BENZINGA

More From Other Websites
Axsome Therapeutics Announces Appointments to Its Board of Directors Sep 17 2014
Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market Sep 16 2014
Today's Thorns, Roses, and All Time Highs... Sep 15 2014
Pluristem & United Therapeutics Progress with Phase I Study Sep 09 2014
United Therapeutics Soars on Remodulin Patent Case Win Sep 02 2014
United Therapeutics (UTHR) Shares March Higher, Can It Continue? Sep 02 2014
United Therapeutics Legal Victory Sends Stock Flying Aug 29 2014
United Therapeutics Up 27% as Patent Win 'Close to a Best Case Scenario' Aug 29 2014
United Therapeutics rises on drug-patent ruling Aug 29 2014
United Therapeutics rises on drug-patent ruling Aug 29 2014
District Court Decision Received In Remodulin Patent Case Aug 29 2014
Catalyst Pharmaceutical Partners (CPRX) Worth Watching: Stock Up 10.3% Aug 26 2014
Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals Aug 25 2014
Can United Therapeutics (UTHR) Keep the Earnings Streak Alive This Quarter? Aug 20 2014
UNITED THERAPEUTICS CORP Financials Aug 02 2014
United Therapeutics (UTHR) Up on Q2 Earnings & Revenue Beat Jul 31 2014
Perilous Reversal Watch: United Therapeutics (UTHR) Jul 30 2014
United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Jul 30 2014
Q2 2014 United Therapeutics Earnings Release - Before Market Open Jul 29 2014
UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition Jul 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK